Last reviewed · How we verify
BLU-5937
BLU-5937 is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons.
BLU-5937 is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons. Used for Chronic cough, Refractory chronic cough.
At a glance
| Generic name | BLU-5937 |
|---|---|
| Also known as | Camlipixant |
| Sponsor | Bellus Health Inc. - a GSK company |
| Drug class | P2X3 receptor antagonist |
| Target | P2X3 |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Neurology |
| Phase | Phase 3 |
Mechanism of action
P2X3 receptors are ion channels expressed on nociceptive (pain-sensing) neurons that mediate acute and chronic pain signals. By antagonizing P2X3, BLU-5937 reduces the transmission of pain signals from peripheral nerves to the central nervous system. This mechanism is particularly relevant for conditions involving visceral and neuropathic pain.
Approved indications
- Chronic cough
- Refractory chronic cough
Common side effects
- Taste disturbance
- Dizziness
- Headache
- Nausea
Key clinical trials
- A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (PHASE3)
- A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (PHASE3)
- Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation (PHASE1)
- Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant (PHASE1)
- Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant (PHASE1)
- Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects (PHASE1)
- A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis (PHASE2)
- Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BLU-5937 CI brief — competitive landscape report
- BLU-5937 updates RSS · CI watch RSS
- Bellus Health Inc. - a GSK company portfolio CI